(Q38118298)

English

Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers

scientific article published on 27 June 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

0 references

0 references

immunohistochemistry

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Nico van Zandwijk

4

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

5

object named as

Sonja Klebe

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

author name string

Douglas W Henderson

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Steven C Kao

3

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

language of work or name

0 references

publication date

27 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Journal of Clinical Pathology

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

847-853

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

The separation of benign and malignant mesothelial proliferations

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Early stages of mesothelioma, screening and biomarkers

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Localized malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Biopsy techniques for the diagnosis of mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Malignant mesothelioma with intracytoplasmic crystalline inclusions.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

BTS statement on malignant mesothelioma in the UK, 2007.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

The diminishing role of surgery in pleural disease

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Pleurodesis outcome in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

What is the best way to diagnose and stage malignant pleural mesothelioma?

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

A local anaesthetic video-assisted thoracoscopy service: prospective performance analysis in a UK tertiary respiratory centre

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Mesothelial markers in high-grade breast carcinoma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Soluble mesothelin-related protein--a blood test for mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Biomarkers for mesothelioma.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Current status of screening for malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Fibulin-3 as a biomarker for pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Biomarkers for malignant pleural mesothelioma: current status

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Molecular biomarkers in malignant mesothelioma: state of the art.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Mesothelin-family proteins and diagnosis of mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Soluble Mesothelin–related Peptides in the Diagnosis of Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201303

21 January 2018

Identifiers

10.1136/JCLINPATH-2012-201303

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38118298&oldid=2175983801"